Hereditary Angioedema

Table of Contents

  1. Overview
  2. Epidemiology
  3. Types of Hereditary Angioedema
  4. Pathophysiology
  5. Clinical Presentation
  6. Diagnosis
  7. Acute Treatment
  8. Long-Term Prophylaxis
  9. Special Populations
  10. Prognosis and Quality of Life
  11. Emerging Therapies
  12. Research Papers
  13. Connections
  14. Featured Videos

Back to Table of Contents

1. Overview

Hereditary angioedema (HAE) is a rare genetic condition causing recurrent episodes of severe swelling (angioedema) that can affect the skin, gastrointestinal tract, and most dangerously the larynx — where untreated swelling can be fatal. Unlike allergic angioedema triggered by histamine, HAE is NOT histamine-mediated. This means antihistamines, epinephrine, and corticosteroids — the standard tools for allergic reactions — do not work for HAE attacks. The underlying mechanism is bradykinin excess: a protein that makes blood vessels leak fluid into surrounding tissues.

Three major types exist:

Historically, HAE carried a 25–40% mortality rate from laryngeal (throat) swelling before effective treatments existed. Modern targeted therapies have transformed this outlook — today, with proper diagnosis and treatment, patients can expect a near-normal life expectancy. The greatest ongoing challenge is the average 8–10 year delay in diagnosis, during which patients are often told they have allergies, irritable bowel syndrome, or psychosomatic pain.

Back to Table of Contents

2. Epidemiology

Back to Table of Contents

3. Types of Hereditary Angioedema

HAE Type 1 (70–85% of Cases)

Caused by a loss-of-function mutation in the SERPING1 gene, resulting in a quantitative deficiency of C1-esterase inhibitor (C1-INH) — both the amount (antigen) and function of the protein are low. Because C1-INH normally keeps complement activation in check, its absence causes continuous low-level complement consumption: C4 levels are chronically low (an extremely useful screening finding). Importantly, C1q levels remain normal — this distinguishes HAE from acquired C1-INH deficiency, where C1q is also consumed.

HAE Type 2 (15% of Cases)

Another SERPING1 mutation, but here the protein is produced at normal or even elevated quantities — it simply doesn't function properly. Lab testing shows normal or high C1-INH antigen but low C1-INH functional activity. C4 is still chronically low for the same reason as Type 1. The clinical presentation is identical to Type 1. This is why it is essential to order both a C1-INH antigen level and a C1-INH functional assay — relying on antigen alone will miss all Type 2 cases.

HAE with Normal C1-INH (Formerly "Type III")

A heterogeneous group with normal C1-INH antigen, function, C4, and C1q. Multiple subtypes have been identified:

Acquired C1-INH Deficiency (AAE — Not Hereditary)

Not a genetic condition, but clinically similar to HAE. The critical distinction: C1q is LOW in acquired deficiency (immune complexes consume it), whereas C1q is normal in hereditary forms. Associated with B-cell lymphomas, monoclonal gammopathy (MGUS), systemic lupus erythematosus, and anti-C1-INH autoantibodies. Typically presents in older adults with no family history. Treatment of the underlying condition is the priority.

Back to Table of Contents

4. Pathophysiology

C1-esterase inhibitor (C1-INH) is a serine protease inhibitor (serpin) that serves as a critical brake on two important biological systems:

  1. Contact activation (kallikrein-kinin) system: C1-INH inhibits plasma kallikrein (which cleaves high molecular weight kininogen [HMWK] to produce bradykinin) and Factor XIIa (which activates kallikrein)
  2. Complement system: C1-INH inhibits C1r and C1s, preventing uncontrolled complement activation

When C1-INH is absent or dysfunctional:

Common HAE attack triggers include:

Back to Table of Contents

5. Clinical Presentation

Prodrome (Warning Signs)

Up to 50% of patients experience a prodrome 48–72 hours before an attack:

Recognizing the prodrome allows early self-treatment, potentially aborting or minimizing the attack.

Attack Types and Characteristics

Subcutaneous (Skin) Edema

The most common attack type. Key distinguishing features:

Abdominal Attacks

Second most common type; affects approximately 80% of HAE patients during their lifetime. These attacks:

Laryngeal (Throat) Attacks — Medical Emergency

The most dangerous manifestation. Swelling of the larynx can rapidly progress to life-threatening airway obstruction:

Facial and Tongue Attacks

Tongue swelling can impair speech and swallowing and may threaten the airway. Periorbital edema (eye swelling) and lip swelling are common and disfiguring but rarely dangerous in isolation. However, face/tongue involvement warrants close monitoring for laryngeal extension.

Back to Table of Contents

6. Diagnosis

Complement Testing

C4 is the best initial screening test for HAE Types 1 and 2:

For HAE with normal C1-INH (FXII and other subtypes), all complement tests are normal. Diagnosis requires a compatible clinical history, often with positive family history, and genetic testing of F12 and other candidate genes.

Genetic Testing

Sequencing of the SERPING1 gene confirms Types 1 and 2 and is invaluable for family screening (first-degree relatives should be tested). Genetic confirmation does not change acute management but matters for family members who may be asymptomatic carriers at risk for future attacks.

When to Test

C4 and C1-INH antigen can be measured at any time — they are chronically abnormal between attacks. Results should be confirmed on two separate occasions due to laboratory variability. Testing is most commonly triggered by: recurrent unexplained angioedema without urticaria, family history of HAE, or a history of recurrent "unexplained" abdominal pain.

Differential Diagnosis

Back to Table of Contents

7. Acute Treatment

Critical principle: HAE attacks do NOT respond to antihistamines, epinephrine, or corticosteroids. All effective acute therapies target either bradykinin production or the bradykinin receptor.

Every HAE patient must: (1) carry two doses of an acute medication at all times, (2) have a written emergency action plan, and (3) ensure that all treating physicians know the diagnosis and that epinephrine/antihistamines are not effective.

Approved Acute Therapies

Laryngeal Attack Protocol

For any HAE patient with throat tightness, hoarseness, or difficulty breathing:

  1. Administer acute HAE medication immediately (do not wait to "see if it gets worse")
  2. Call emergency services (911) simultaneously
  3. Go to the emergency department regardless of initial response to treatment
  4. If intubation is needed, alert the provider that HAE edema distorts airway anatomy — early fiberoptic or video laryngoscopy is preferred; have surgical airway tools ready

Back to Table of Contents

8. Long-Term Prophylaxis

Short-Term Prophylaxis (Before Procedures)

Any surgical, dental, or medical procedure that could trigger an attack (especially anything involving the upper airway — tracheal intubation is one of the highest-risk triggers) requires prophylaxis:

Long-Term Prophylaxis (Reducing Attack Frequency)

Consider for patients with frequent, severe, or unpredictable attacks, or those with significant quality-of-life impairment. All patients should have acute medication regardless of prophylaxis status.

Back to Table of Contents

9. Special Populations

Pregnancy

HAE management in pregnancy requires careful consideration. Attack frequency often changes during pregnancy — commonly worsens in the first trimester (low estrogen phase), may improve in the second and third trimesters (high progesterone), and frequently worsens in the immediate postpartum period.

Pediatrics

HAE frequently presents in childhood — the average age of first attack is between 8 and 13 years, with peak severity often at puberty. Children with a positive family history should be screened at birth (cord blood C4/C1-INH).

ACE Inhibitors — Absolute Contraindication

ACE inhibitors are absolutely contraindicated in HAE. Angiotensin-converting enzyme is responsible for degrading bradykinin — blocking it causes bradykinin to accumulate, precipitating and dramatically worsening HAE attacks. This applies even in patients with compelling cardiovascular indications (hypertension, heart failure). Use angiotensin receptor blockers (ARBs) as an alternative if a renin-angiotensin system agent is needed — ARBs have a much lower risk of bradykinin accumulation.

Estrogen-Containing Medications

Estrogen upregulates the kallikrein-kinin system, increasing bradykinin production and HAE attack frequency. Estrogen-containing oral contraceptive pills (OCPs), hormone replacement therapy (HRT), and fertility treatments (gonadotropins, clomiphene) can cause dramatic worsening — sometimes triggering attacks in previously mild patients or even unmasking undiagnosed HAE. Patients should use progestin-only contraception. The FXII-HAE subtype is particularly estrogen-sensitive and is often first diagnosed during OCP initiation.

Back to Table of Contents

10. Prognosis and Quality of Life

With modern treatment and proper education, HAE patients can expect near-normal life expectancy. The historical 25–40% mortality from laryngeal attacks has dropped to under 1% in countries with access to appropriate therapies — primarily due to patient education, widespread availability of self-injectable acute medications, and effective long-term prophylaxis.

However, untreated or undertreated HAE carries substantial burden:

With lanadelumab or C1-INH prophylaxis, attack rates reduce by 87–89%, and nearly half of patients achieve complete freedom from attacks. Comprehensive care — including an HAE specialist, individualized prophylaxis, self-injectable acute medication, an emergency action plan, and psychological support — allows most patients to lead full, active lives.

Back to Table of Contents

11. Emerging Therapies

The HAE treatment pipeline is one of the most active in rare disease medicine, driven by the clear therapeutic target (bradykinin and kallikrein) and the availability of biomarkers (C4, bradykinin levels).

Back to Table of Contents

12. Research Papers

Search PubMed for the latest peer-reviewed research on hereditary angioedema:

  1. Hereditary angioedema treatment
  2. C1 esterase inhibitor deficiency
  3. Icatibant hereditary angioedema
  4. Lanadelumab HAE prophylaxis
  5. Bradykinin angioedema
  6. Hereditary angioedema diagnosis
  7. C1-INH concentrate therapy
  8. HAE laryngeal edema
  9. Hereditary angioedema genetics
  10. Berotralstat kallikrein inhibitor
  11. HAE acute attack management
  12. HAE quality of life

Back to Table of Contents

Connections

Back to Table of Contents